LifeSciVC

AUGUST 21, 2024

An adverse event or serious adverse event (SAE) that turns out NOT to be related to the drug may take a while to sort out. Keeping ahead of schedule will help to maintain manufacturing efficiencies, ensure adequate supply and product quality, and meet development timelines.

Clinical Trials 77

Clinical Trials Trials Disease Treatment 77

The Pharma Data

JANUARY 10, 2021

Among the factors that may result in differences are MorphoSys’ expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical (..)

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

NOVEMBER 18, 2020

Events after Q3’2020. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME.

Trials 40

Trials Clinical Supply Production Therapies 40

The Pharma Data

NOVEMBER 22, 2020

Molecular Partners is also collaborating with AGC Biologics, Baccinex, and Ivers-Lee Clinical Supply Management (IL-CSM) to support development of its anti-COVID-19 program, and has reached an agreement with the Swiss Government regarding rights to purchase up to 3.2 million doses of MP0420, if it is approved in Switzerland.

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

JANUARY 24, 2021

In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

OCTOBER 27, 2020

During the clinical development stage, Molecular Partners will provide clinical supply. The companies will work together to scale-up manufacturing capacity, in collaboration with Sandoz, the generics and biosimilar Novartis division, to provide worldwide supply.

Therapies 40

Therapies Virus Treatment Clinical Trials 40

PPD

FEBRUARY 3, 2025

By leveraging an eCDS, the release of key materials such as the full protocol synopsis and schedule of events can occur alongside the feasibility survey. 1 provider of clinical research solutions , our teams deliver 1.5x Recognized as the 2024 No.

Clinical Trials 52

Clinical Trials Trials Clinical Supply Drug Development 52